Oral immunotherapy for peanut allergy (PACE): a syste efficacy and safety

Lancet, The

393, 2222-2232

DOI: 10.1016/s0140-6736(19)30420-9

Citation Report

#	Article	IF	Citations
1	Food OIT. Annals of Allergy, Asthma and Immunology, 2019, 123, 118-119.	0.5	2
2	Food allergy desensitisation: a hard nut to crack?. Archives of Disease in Childhood, 2019, 104, 1021-1022.	1.0	8
3	Molecular Targeting Nanoprobes with Non-Overlap Emission in the Second Near-Infrared Window for in Vivo Two-Color Colocalization of Immune Cells. ACS Nano, 2019, 13, 12830-12839.	7.3	44
4	Sustained unresponsiveness in peanut oral immunotherapy. Lancet, The, 2019, 394, 1392-1393.	6.3	5
5	Identification of goals and barriers to treatment from 92 consecutive consultations with families considering peanut oral immunotherapy. , 2019, 7, 251513551986976.	1.4	4
7	Recent developments and highlights in food allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2355-2367.	2.7	66
8	Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet, The, 2019, 394, 1437-1449.	6.3	215
9	Pollen-Food Allergy Syndrome: A not so Rare Disease in Childhood. Medicina (Lithuania), 2019, 55, 641.	0.8	56
10	ICER report for peanut OIT comes up short. Annals of Allergy, Asthma and Immunology, 2019, 123, 430-432.	0.5	15
12	Peanut oral immunotherapy: balancing benefits and risks for individuals. Lancet, The, 2019, 393, 2180-2181.	6.3	7
13	Peanut immunotherapy increases allergic and anaphylactic reactions, finds review. BMJ: British Medical Journal, 2019, 365, l1912.	2.4	0
15	Peanut allergy: Burden of illness. Allergy and Asthma Proceedings, 2019, 40, 290-294.	1.0	25
16	Peanut Oral Immunotherapy: Is It Safer in Preschoolers than in Older Age Groups?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2768-2769.	2.0	1
17	Oral and sublingual immunotherapy for food allergy. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 606-613.	1.1	25
18	Current perspectives on peanut allergy. Internal Medicine Journal, 2019, 49, 1480-1487.	0.5	3
20	Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity. Journal of Allergy and Clinical Immunology, 2020, 145, 229-238.	1.5	32
21	Long-term prognosis after wheat oral immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 371-374.e5.	2.0	6
22	Are avoidance diets still warranted in children with atopic dermatitis?. Pediatric Allergy and Immunology, 2020, 31, 19-26.	1.1	40

#	Article	IF	Citations
23	Peanut oral immunotherapy induces blocking antibodies but does not change the functional characteristics of peanut-specific IgE. Journal of Allergy and Clinical Immunology, 2020, 145, 440-443.e5.	1.5	22
24	Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?. Journal of Allergy and Clinical Immunology, 2020, 145, 1153-1156.	1.5	17
25	The value of oral immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1291-1293.	2.7	5
26	Health aspects of peanuts as an outcome of its chemical composition. Food Science and Human Wellness, 2020, 9, 21-30.	2.2	81
27	Ferroptosis-driven nanotherapeutics for cancer treatment. Journal of Controlled Release, 2020, 319, 322-332.	4.8	130
28	Reaction phenotypes in IgE-mediated food allergy and anaphylaxis. Annals of Allergy, Asthma and Immunology, 2020, 124, 473-478.	0.5	34
29	Food Allergy Immunotherapy with Adjuvants. Immunology and Allergy Clinics of North America, 2020, 40, 149-173.	0.7	13
30	Peanut Oral Immunotherapy. Immunology and Allergy Clinics of North America, 2020, 40, 97-110.	0.7	14
31	Novel Therapies for Treatment of Food Allergy. Immunology and Allergy Clinics of North America, 2020, 40, 175-186.	0.7	24
32	The Efficacy and Safety of Epicutaneous Immunotherapy for Allergic Diseases: A Systematic Review and Meta-Analysis. International Archives of Allergy and Immunology, 2020, 181, 170-182.	0.9	19
33	Safety of Food Oral Immunotherapy. Immunology and Allergy Clinics of North America, 2020, 40, 111-133.	0.7	16
34	Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE. Journal of Allergy and Clinical Immunology, 2020, 145, 885-896.e6.	1.5	86
35	Dietary and Microbial Determinants in Food Allergy. Immunity, 2020, 53, 277-289.	6.6	49
36	Bioactive metal-containing nanomaterials for ferroptotic cancer therapy. Journal of Materials Chemistry B, 2020, 8, 10461-10473.	2.9	20
37	The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 620-623.	0.5	6
38	The Gut Microbiome and the Big Eight. Nutrients, 2020, 12, 3728.	1.7	19
39	Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt. International Journal of Molecular Sciences, 2020, 21, 8267.	1.8	13
40	Novel Approaches to Food Allergy Management During COVID-19 Inspire Long-Term Change. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2851-2857.	2.0	46

#	Article	IF	Citations
41	Community Private Practice Clinical Experience with Peanut Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2727-2735.	2.0	27
42	Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. The Lancet Child and Adolescent Health, 2020, 4, 728-739.	2.7	106
43	Harnessing Newtonâ€™s third-law paradigm to treat autoimmune diseases and chronic inflammations. Inflammation Research, 2020, 69, 813-824.	1.6	1
44	Shared decision-making in the care of a patient with food allergy. Annals of Allergy, Asthma and Immunology, 2020, 125, 262-267.	0.5	25
45	Eosinophilic esophagitis as a complication of food oral immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 616-623.	1.1	12
46	Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003) Tj ETQq1 1 0.784314 rgBT /Ove	0.8	5
47	Tolerance-inducing medicines in autoimmunity: rheumatology and beyond. Lancet Rheumatology, The, 2020, 2, e565-e575.	2.2	10
48	Food allergy oral immunotherapy. Journal of Food Allergy, 2020, 2, 75-80.	0.1	10
49	Oral Immunotherapy for Treatment of Peanut Allergy. Journal of Investigative Medicine, 2020, 68, 1152-1155.	0.7	16
50	Immunological Outcomes of Allergen-Specific Immunotherapy in Food Allergy. Frontiers in Immunology, 2020, 11, 568598.	2.2	53
51	Emerging Therapies for Peanut Allergy. Journal of Pharmacy Practice, 2020, , 089719002097076.	0.5	6
52	Oral immunotherapy for peanut allergy: The pro argument. World Allergy Organization Journal, 2020, 13, 100455.	1.6	20
53	A Potential Role for Epigenetically Mediated Trained Immunity in Food Allergy. IScience, 2020, 23, 101171.	1.9	18
54	Novel insights regarding anaphylaxis in children â€•With a focus on prevalence, diagnosis, and treatment. Pediatric Allergy and Immunology, 2020, 31, 879-888.	1.1	20
55	Peanut oral immunotherapy protects patients from accidental allergic reactions to peanut. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2437-2441.e3.	2.0	24
56	Food Allergy Management at School in the Era of Immunotherapy. Current Allergy and Asthma Reports, 2020, 20, 32.	2.4	7
57	Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit. Journal of Allergy and Clinical Immunology, 2020, 146, 244-249.	1.5	45
58	Production of allergen-specific immunotherapeutic agents for the treatment of food allergy. Critical Reviews in Biotechnology, 2020, 40, 881-894.	5.1	8

#	Article	IF	Citations
60	CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy, Asthma and Clinical Immunology, 2020, 16, 20.	0.9	100
61	Food Allergy Insights: A Changing Landscape. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 8.	1.0	17
62	Pros and cons of pre-emptive screening programmes before peanut introduction in infancy. The Lancet Child and Adolescent Health, 2020, 4, 526-535.	2.7	21
63	A counseling video with pre- and posttesting and checklist for oral immunotherapy consent improves participant knowledge. Annals of Allergy, Asthma and Immunology, 2020, 125, 468-474.e4.	0.5	13
65	Sublingual immunotherapy for food allergy and its future directions. Immunotherapy, 2020, 12, 921-931.	1.0	21
66	Outcomes for clinical trials of food allergy treatments. Annals of Allergy, Asthma and Immunology, 2020, 125, 535-542.	0.5	11
67	Pharmacotherapy in allergy medicine: from â€˜ipse dixitâ€™ to the evidence-based medicine. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 407-413.	1.1	1
68	Unmet needs of children with peanut allergy. Annals of Allergy, Asthma and Immunology, 2020, 124, 479-486.	0.5	21
69	Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1337-1346.	2.7	57
70	Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies. Annals of Allergy, Asthma and Immunology, 2020, 125, 90-96.	0.5	36
71	Vaccination against Allergy: A Paradigm Shift?. Trends in Molecular Medicine, 2020, 26, 357-368.	3.5	24
72	New Perspectives in Food Allergy. International Journal of Molecular Sciences, 2020, 21, 1474.	1.8	130
73	Perception of severity of adverse events in oral immunotherapy â€“ Authors' reply. Lancet, The, 2020, 395, 415-416.	6.3	1
74	Perception of severity of adverse events in oral immunotherapy. Lancet, The, 2020, 395, 415.	6.3	5
75	Food reactions during avoidance. Annals of Allergy, Asthma and Immunology, 2020, 124, 459-465.	0.5	17
76	Immunotherapy approaches for peanut allergy. Expert Review of Clinical Immunology, 2020, 16, 167-174.	1.3	13
77	Current Controversies and Future Prospects for Peanut Allergy Prevention, Diagnosis and Therapies . Journal of Asthma and Allergy, 2020, Volume 13, 51-66.	1.5	9
78	New Developments in Non-allergen-specific Therapy for the Treatment of Food Allergy. Current Allergy and Asthma Reports, 2020, 20, 3.	2.4	22

#	Article	IF	Citations
79	Adverse events associated with peanut oral immunotherapy in children â€“ a systematic review and meta-analysis. Scientific Reports, 2020, 10, 659.	1.6	24
80	Oral desensitization in IgEâ€mediated food allergy: Effectiveness and safety. Pediatric Allergy and Immunology, 2020, 31, 49-50.	1.1	12
81	Quality of life of children aged 8â€12 years undergoing food allergy oral immunotherapy: Child and parent perspective. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2623-2632.	2.7	31
82	Handling of allergen immunotherapy in the COVIDâ€19 pandemic: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1546-1554.	2.7	87
83	Peanut Oral Immunotherapy: a Current Perspective. Current Allergy and Asthma Reports, 2020, 20, 14.	2.4	40
84	Peanut Allergy: New Advances and Ongoing Controversies. Pediatrics, 2020, 145, .	1.0	29
85	Past, present, and future of allergen immunotherapy vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 131-149.	2.7	66
86	Patient Characteristics and Risk Factors for Home Epinephrine-Treated Reactions During Oral Immunotherapy for Food Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 185-192.e3.	2.0	24
87	Five-year follow-up of early intervention peanut oral immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 514-517.	2.0	17
88	First Real-World Effectiveness Analysis of Preschool Peanut Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1349-1356.e1.	2.0	41
89	Allergies alimentaires. , 2021, , 67-112.		0
90	Integrating oral immunotherapy into clinical practice. Journal of Allergy and Clinical Immunology, 2021, 147, 1-13.	1.5	28
91	Oral tolerance as antigen-specific immunotherapy. Immunotherapy Advances, 2021, 1, .	1.2	12
92	ImmunothÃ©rapie orale pour les allergies alimentaires. , 2021, , 259-267.		0
93	Recent advances in the management of nut allergy. World Allergy Organization Journal, 2021, 14, 100491.	1.6	18
94	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). Allergologie Select, 2021, 5, 251-259.	1.6	9
95	Regulation of oral antigen delivery early in life: Implications for oral tolerance and food allergy. Clinical and Experimental Allergy, 2021, 51, 518-526.	1.4	16
96	Update on food allergy. Pediatric Allergy and Immunology, 2021, 32, 647-657.	1.1	66

#	Article	IF	Citations
97	Diagnosis and basic management of associated allergic conditions. , 2021, , 414-421.		0
98	Addressing risk management difficulties in children with food allergies. Pediatric Allergy and Immunology, 2021, 32, 658-666.	1.1	11
99	La desensibilizzazione orale nellâ€™allergia alimentare: certezze, dubbi e prospettive. Medico E Bambino, 2021, 40, 74-75.	0.1	2
100	Current developments in the treatment of peanut allergy. Allergo Journal International, 2021, 30, 56-63.	0.9	1
101	Oral immunotherapy: The answer to peanut allergy?. Cleveland Clinic Journal of Medicine, 2021, 88, 104-109.	0.6	3
103	Emerging developments in the forefront of peanut oral immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 263-268.	1.1	3
104	Allergen Preparation in AIT, Now and in the Future. Current Treatment Options in Allergy, 2021, 8, 120-132.	0.9	2
105	Role of doctors and other medical professions in the care of patients with allergies. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2021, 35, 8-13.	0.0	0
106	Weighing the benefits and risks of oral immunotherapy in clinical practice. Allergy and Asthma Proceedings, 2021, 42, 118-123.	1.0	9
109	A Practical, Stepwise Approach to Peanut Oral Immunotherapy in Clinical Practice: Benefits and Risks. Journal of Asthma and Allergy, 2021, Volume 14, 277-285.	1.5	5
110	The Cost-Effectiveness of Preschool Peanut Oral Immunotherapy in the Real-World Setting. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2876-2884.e4.	2.0	16
111	How to Incorporate Oral Immunotherapy into Your Clinical Practice. Current Allergy and Asthma Reports, 2021, 21, 30.	2.4	11
112	Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcÎµRIâ€“Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge. Journal of Immunology, 2021, 206, 2290-2300.	0.4	39
113	Biologics and Novel Therapies for Food Allergy. Immunology and Allergy Clinics of North America, 2021, 41, 271-283.	0.7	11
115	Oral immunotherapy in food allergies: A practical update for pediatricians. Archives De Pediatrie, 2021, 28, 319-324.	0.4	13
116	Peanut Oral Immunotherapy: Is the Second Year the Charm?. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1890-1891.	2.0	1
117	An Approach to the Office-Based Practice of Food Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1826-1838.e8.	2.0	44
118	A High Proportion of Canadian Allergists Offer Oral Immunotherapy but Barriers Remain. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1902-1908.	2.0	10

#	Article	IF	Citations
119	The 2021 AAAAI Foundation Faculty Development awardees. Journal of Allergy and Clinical Immunology, 2021, 147, 1629-1633.	1.5	2
120	Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1879-1889.e13.	2.0	53
121	Peanut Immunotherapy: Practical Applications. Current Treatment Options in Allergy, 2021, 8, 242-260.	0.9	0
122	New Insights in Therapy for Food Allergy. Foods, 2021, 10, 1037.	1.9	19
123	The use of biologics in food allergy. Clinical and Experimental Allergy, 2021, 51, 1006-1018.	1.4	46
124	Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy. Clinical Gastroenterology and Hepatology, 2021, 19, 1151-1159.e14.	2.4	41
125	Improvement in Health-Related Quality of Life in Food-Allergic Patients: A Meta-Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3705-3714.	2.0	21
126	Oral Immunotherapyâ€"Related Awareness, Attitudes, and Experiences Among a Nationally Representative Sample of Food Allergy Patients/Caregivers. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4087-4094.e3.	2.0	10
127	The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy. Frontiers in Immunology, 2021, 12, 660974.	2.2	13
128	Biologics as treatment options for anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 455-464.	1.1	7
129	Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 33	0.8	8
130	Anaphylaxis knowledge gaps and future research priorities: AÂconsensus report. Journal of Allergy and Clinical Immunology, 2022, 149, 999-1009.	1.5	21
131	Peanut allergy: Beyond the oral immunotherapy plateau. Clinical and Translational Allergy, 2021, 11, e12046.	1.4	3
132	Canadian food ladders for dietary advancement in children with IgE-mediated allergy to milk and/or egg. Allergy, Asthma and Clinical Immunology, 2021, 17, 83.	0.9	18
133	Long-term benefit of probiotic peanut oral immunotherapy on quality of life in a randomized trial. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4493-4495.e1.	2.0	9
134	Achieving Precision Medicine in Allergic Disease: Progress and Challenges. Frontiers in Immunology, 2021, 12, 720746.	2.2	14
135	Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy. Frontiers in Immunology, 2021, 12, 613461.	2.2	17
136	Caregiver perceptions and attitudes associated with oral immunotherapy on social media. Allergy and Asthma Proceedings, 2021, 42, 432-438.	1.0	3

#	Article	IF	Citations
137	Mechanisms for Alternaria alternata Function in the Skin During Induction of Peanut Allergy in Neonatal Mice With Skin Barrier Mutations. Frontiers in Allergy, 2021, 2, 677019.	1.2	5
138	Management of Eosinophilic Esophagitis During Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3282-3287.	2.0	12
139	From Allergen Molecules to Molecular Immunotherapy of Nut Allergy: A Hard Nut to Crack. Frontiers in Immunology, 2021, 12, 742732.	2.2	17
140	Heterogeneity in Parent Preferences for Peanut Desensitization Therapy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3459-3465.	2.0	1
141	Oral Immunotherapy for Food-Allergic Children: A Pro-Con Debate. Frontiers in Immunology, 2021, 12, 636612.	2.2	25
142	Antihistamine premedication improves safety and efficacy of allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2021, 127, 363-371.e1.	0.5	9
143	Home epinephrine-treated reactions in food allergy oral immunotherapy. Annals of Allergy, Asthma and Immunology, 2021, 127, 451-455.e1.	0.5	8
144	Allergic disorders. , 2021, , 390-434.		0
145	Recent progress on nanomedicine-induced ferroptosis for cancer therapy. Biomaterials Science, 2021, 9, 5092-5115.	2.6	38
146	Current Insights into Immunotherapy Approaches for Food Allergy. ImmunoTargets and Therapy, 2021, Volume 10, 1-8.	2.7	12
148	Slow low-dose oral immunotherapy: Threshold and immunological change. Allergology International, 2020, 69, 601-609.	1.4	29
149	Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergology International, 2020, 69, 549-560.	1.4	92
150	Food allergy: epidemiology, pathogenesis, diagnosis, prevention, and treatment. Current Opinion in Immunology, 2020, 66, 57-64.	2.4	63
151	Oral immunotherapy for peanut allergy: The con argument. World Allergy Organization Journal, 2020, 13, 100445.	1.6	7
152	Novel vaccines for allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 86-99.	1.1	12
153	Prevention of food allergy: can we stop the rise of IgE mediated food allergies?. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 195-201.	1.1	4
154	Food allergy: an updated review on pathogenesis, diagnosis, prevention and management. Acta Biomedica, 2020, 91, e2020012.	0.2	15
155	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergologie Select, 2020, 4, 44-52.	1.6	23

#	Article	IF	Citations
156	Oral Immunotherapy for Children with Cowâ€™s Milk Allergy. Pathogens, 2021, 10, 1328.	1.2	5
157	Translating Evidence to Optimize Patient Care Using GRADE. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4221-4230.	2.0	30
158	Transcriptome changes during peanut oral immunotherapy and omalizumab treatment. Pediatric Allergy and Immunology, 2022, 33, e13682.	1.1	8
159	High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy. Cell Reports Medicine, 2021, 2, 100410.	3.3	25
160	IgE Immunoapheresis for Treatment of Pediatric Patients with Severe Asthma and Multiple Food Anaphylaxis: a Pilot Study. World Allergy Organization Journal, 2020, 13, 100417.	1.6	0
161	A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy. PLoS ONE, 2020, 15, e0241648.	1.1	2
165	Food Allergy: Searching for the Modern Environmental Culprit. Yale Journal of Biology and Medicine, 2020, 93, 733-747.	0.2	1
166	Advances in Food Allergy Treatment. Yale Journal of Biology and Medicine, 2020, 93, 749-758.	0.2	0
167	Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1864-1873.e10.	2.0	31
168	Biomimetic Nanomaterials Triggered Ferroptosis for Cancer Theranostics. Frontiers in Chemistry, 2021, 9, 768248.	1.8	11
169	Advances, Practical Implementation, and Unmet Needs Regarding Oral Immunotherapy for Food Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 19-33.	2.0	14
170	Treatment Approaches to Food Allergy. Handbook of Experimental Pharmacology, 2021, 268, 173-193.	0.9	3
171	Triggers for Home Epinephrine-Treated Reactions During Oral Immunotherapy for Food Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1070-1076.e2.	2.0	7
172	Peanut oral immunotherapy in very young children. Lancet, The, 2022, 399, 336-337.	6.3	6
173	Cashew oral immunotherapy for desensitizing cashewâ€pistachio allergy (NUT CRACKER study). Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1863-1872.	2.7	25
174	Allergen immunotherapy and/or biologicals for IgEâ€mediated food allergy: A systematic review and metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1852-1862.	2.7	58
175	Peanut oral immunotherapy: current trends in clinical trials. Immunotherapy Advances, 2022, 2, .	1.2	5
176	Allergen immunotherapy for long-term tolerance and prevention. Journal of Allergy and Clinical Immunology, 2022, 149, 802-811.	1.5	21

#	Article	IF	Citations
177	Immunotherapy Effectiveness in Treating Peanut Hypersensitivity: A Systemic Review. Cureus, 2022, 14, e21832.	0.2	1
178	Allergen immunotherapy for allergic airway diseases: Use lessons from the past to design a brighter future. , 2022, 237, 108115.		9
179	Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. The Lancet Child and Adolescent Health, 2022, 6, 171-184.	2.7	55
180	The Road Toward Transformative Treatments for Food Allergy. Frontiers in Allergy, 2022, 3, 826623.	1.2	6
181	Oral Immunotherapy in Food Allergy: A Critical Pediatric Perspective. Frontiers in Pediatrics, 2022, 10, 842196.	0.9	7
182	Oral immunotherapy for food allergy in children: is it worth it?. Expert Review of Clinical Immunology, 2022, 18, 363-376.	1.3	7
183	Oral desensitization therapy for peanut allergy induces dynamic changes in peanutâ€specific immune responses. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2534-2548.	2.7	20
184	Food allergen ladders: A need for standardization. Pediatric Allergy and Immunology, 2022, 33, .	1.1	21
185	Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials. Journal of Allergy and Clinical Immunology, 2022, 149, 2043-2052.e9.	1.5	16
187	Palforzia for peanut allergy: Panacea or predicament. Clinical and Experimental Allergy, 2022, 52, 729-731.	1.4	9
188	Peanut Allergy â€“ No Longer a Life Sentence. Acta Medica Academica, 2020, 49, 198.	0.3	0
189	World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cowâ€™s Milk Allergy (DRACMA) Guideline update â€“ XIV â€“ Recommendations on CMA immunotherapy. World Allergy Organization Journal, 2022, 15, 100646.	1.6	18
190	Probiotic peanut oral immunotherapy is associated with longâ€term persistence of 8â€week sustained unresponsiveness and longâ€lasting qualityâ€ofâ€life improvement. Clinical and Experimental Allergy, 2022, 52, 806-811.	1.4	4
191	Oral administration of Lactiplantibacillus plantarum 22A-3 exerts anti-allergic activity against intestinal food allergy mouse models sensitized and challenged with ovalbumin. Food Bioscience, 2022, , 101785.	2.0	2
192	Immunotherapies in the treatment of immunoglobulin Eâ€‘mediated allergy: Challenges and scope for innovation (Review). International Journal of Molecular Medicine, 2022, 50, .	1.8	0
193	Peanut Oral Immunotherapy With or Without H1 and H2 Antihistamine Premedication for Peanut Allergy (PISCES): A Placebo-Controlled Randomized Clinical Trial. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2386-2394.	2.0	10
194	Emerging Hop Japanese Pollinosis in Asia. Current Protein and Peptide Science, 2022, 23, 714-720.	0.7	3
195	Nanotherapeutics for hydrogen sulfide-involved treatment: An emerging approach for cancer therapy. Nanotechnology Reviews, 2022, 11, 2320-2348.	2.6	3

#	Article	IF	Citations
196	The Roles of Cloud-Based Systems on the Cancer-Related Studies: A Systematic Literature Review. IEEE Access, 2022, 10, 64126-64145.	2.6	3
197	Mast Cell Desensitization in Allergen Immunotherapy. Frontiers in Allergy, 0, 3, .	1.2	5
198	Patient selection for milk and egg ladders using a food ladder safety checklist. Allergy, Asthma and Clinical Immunology, 2022, 18, .	0.9	10
199	Comment on EAACI guideline: Anaphylaxis (2021 update). Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2268-2268.	2.7	1
200	Measuring the Impact of Food Immunotherapy on Health-Related Quality of Life in Clinical Trials. Frontiers in Allergy, 0, 3, .	1.2	6
201	Risk factors for reactions and adverse effects during oral immunotherapy. Journal of Food Allergy, 2022, 4, 60-64.	0.1	4
202	Considerations for a shared decision-making conversation when initiating food oral immunotherapy. Journal of Food Allergy, 2022, 4, 53-59.	0.1	8
203	Efficacy, effectiveness and other patient-centered outcomes of oral immunotherapy. Journal of Food Allergy, 2022, 4, 28-33.	0.1	3
204	Optimal patient selection for oral immunotherapy. Journal of Food Allergy, 2022, 4, 49-52.	0.1	4
205	A practical focus on oral immunotherapy to tree nuts. Journal of Food Allergy, 2022, 4, 120-126.	0.1	1
206	Epithelial barrier regulation, antigen sampling, and food allergy. Journal of Allergy and Clinical Immunology, 2022, 150, 493-502.	1.5	6
207	Transitioning peanut oral immunotherapy to clinical practice. Frontiers in Allergy, 0, 3, .	1.2	3
208	Treatment for food allergy: Current status and unmet needs. Journal of Allergy and Clinical Immunology, 2023, 151, 1-14.	1.5	14
209	Value-Based, Cost-Effective Care: The Role of the Allergist-Immunologist. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 132-139.	2.0	6
210	Inmunoterapia con alÃ©rgenos para enfermedades alÃ©rgicas de las vÃas respiratorias: Aprovechar las lecciones del pasado para diseÃ±ar un futuro mejor. Karger Kompass NeumologÃa, 2022, 4, 58-80.	0.0	0
211	Guideline on allergen immunotherapy in IgE-mediated allergic diseases. Allergologie Select, 2022, 6, 167-232.	1.6	39
212	Patientâ€oriented allergy. Clinical and Experimental Allergy, 2022, 52, 1012-1014.	1.4	1
213	Induction of food-specific IgG byÂGene Gun-delivered DNA vaccines. Frontiers in Allergy, 0, 3, .	1.2	4

#	Article	IF	Citations
214	Information needs of patients considering oral immunotherapy for food allergy. Clinical and Experimental Allergy, 2022, 52, 1391-1402.	1.4	11
215	Should We Pretreat Before We Go Nuts? Antihistamines Modestly Reduce the Side Effects of Peanut Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2395-2396.	2.0	1
216	World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's MilkÂAllergy (DRACMA) guideline update â€“ XIII â€“ Oral immunotherapy for CMA â€“ Systematic review. World Allergy Organization Journal, 2022, 15, 100682.	1.6	6
217	Tree nut allergy: a systematic review. Current Opinion in Pediatrics, 2022, 34, 600-608.	1.0	3
219	Management of IgEâ€mediated food allergy in the 21st century. Clinical and Experimental Allergy, 2023, 53, 25-38.	1.4	9
220	Progress in Oral Immunotherapy of Food Allergy in Children. Advances in Clinical Medicine, 2022, 12, 8871-8876.	0.0	0
221	Oral, sublingual, and dermatologic immunotherapy for food allergy. , 2022, , 1039-1076.		0
222	Angioedema of Vermilion Border Lip: A Case Report. Cureus, 2022, , .	0.2	0
223	Allergen immunotherapy: past, present and future. Nature Reviews Immunology, 2023, 23, 317-328.	10.6	70
224	Current and future treatments for peanut allergy. Clinical and Experimental Allergy, 0, , .	1.4	4
225	Food Allergy and Eosinophilic Gastrointestinal Diseasesâ€”The Next 10 Years. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 72-78.	2.0	6
226	Factors associated with home epinephrine-treated reactions during peanut and tree-nut oral immunotherapy. Annals of Allergy, Asthma and Immunology, 2023, 130, 340-346.e5.	0.5	2
227	Early life gut microbiota: Consequences for health and opportunities for prevention. Critical Reviews in Food Science and Nutrition, 0, , 1-25.	5.4	4
228	Children and caregiver proxy quality of life from peanut oral immunotherapy trials. Clinical and Translational Allergy, 2022, 12, .	1.4	6
229	Oral immunotherapy. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2022, 36, 547-553.	0.0	0
230	Oral immunotherapy for food allergy: What's age got to do with it?. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 626-628.	2.7	0
232	Food Allergen Immunotherapy in Preschool Children: Do We Have the Evidence?. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 1028-1035.	2.0	5
233	Oral immunotherapy using boiled peanuts for treating peanut allergy: An openâ€label, singleâ€arm trial. Clinical and Experimental Allergy, 2023, 53, 327-336.	1.4	5

#	Article	IF	Citations
234	App providing psychosocial and educational supports benefits caregivers of children with newly diagnosed food allergies. Journal of Food Allergy, 2022, 4, 163-171.	0.1	0
235	Anti-IgE for food allergy. Annals of Allergy, Asthma and Immunology, 2023, , .	0.5	2
236	Endpoints and Outcomes After Immunotherapy for Food Allergy: What Is Meaningful for Patients?. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 998-1007.	2.0	2
237	Comparing the risk of anaphylaxis requiring epinephrine in oral immunotherapy and subcutaneous immunotherapy: AÂreview of recent Canadian real-world literature. , 2023, 2, 100080.		0
239	Oral immunotherapy for food allergy: Translation from studies to clinical practice?. World Allergy Organization Journal, 2023, 16, 100747.	1.6	8
240	Varying Approaches to Management of IgE-Mediated Food Allergy in Children Around theÂWorld. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 1010-1027.e6.	2.0	5
241	Anaphylaxis: severity determination, grading systems. , 2022, , .		0
242	Dose and route of administration determine the efficacy of prophylactic immunotherapy for peanut allergy in a Brown Norway rat model. Frontiers in Immunology, 0, 14, .	2.2	2
243	A clinical focus on oral tolerance in the development, prevention, and management of food allergy. Cellular Immunology, 2023, 386, 104693.	1.4	4
244	Oral Immunotherapy. Primary Care - Clinics in Office Practice, 2023, 50, 269-281.	0.7	2
245	The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders. Journal of Allergy and Clinical Immunology, 2023, 151, 595-606.	1.5	9
246	Evening ingestion as a potential reaction cofactor during peanut oral immunotherapy in children. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 1964-1966.e2.	2.0	1
247	Severe Anaphylactic Reactions to Home Doses of Oral Immunotherapy for Food Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 2524-2533.e3.	2.0	4
248	Appropriate dose for oral food challenge for severe peanut allergy. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2023, 37, 93-98.	0.0	0
249	Risk factors associated with safety of preschool peanut oral immunotherapy. , 2023, 2, 100094.		1
250	Viewing Pediatric Food Oral Immunotherapy Through an Ethical Lensâ€"A Narrative Systematic Review. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 1914-1925.	2.0	1
251	Basophil activation test. , 2022, , .		0
253	Oral Immunotherapy in Food Allergy: Where Are We Now?. Allergy, Asthma and Immunology Research, 2023, 15, 125.	1.1	1

#	Article	IF	Citations
254	Allergen Immunotherapy for Allergic Diseases. , 2023, , 1117-1126.		0
255	Ara h 2â€specific IgE epitopeâ€like peptides inhibit the binding of IgE to Ara h 2 and suppress IgEâ€dependent effector cell activation. Clinical and Experimental Allergy, 2023, 53, 636-647.	1.4	3
270	Peanut Allergy. , 2023, , .		0
271	Food-associated exercise-induced allergy and augmentation factors. , 2023, , .		0
280	Eosinophil-Associated Gastrointestinal Manifestations During OIT. Clinical Reviews in Allergy and Immunology, 2023, 65, 365-376.	2.9	0
282	Oral immunotherapy for peanut allergy. , 2023, , .		0
283	Clinical outcome measures in food allergy treatment. , 2023, , .		0
298	Update in Pediatric Allergy. , 2023, , 61-75.		0
309	Epicutaneous immunotherapy. , 2024, , .		0